 |
|
New York State
Meningitis Information
You must read the following New York State Meningitis Information before signing
the required Meningitis Response Form found
here.
New York State Department of
Health
|
Last Reviewed: November 2006 |
|
What is
meningococcal disease? |
|
Meningococcal disease is a severe bacterial infection of the
bloodstream or meninges (a thin lining covering the brain and spinal
cord) caused by the meningococcus germ.
|
|
Who gets
meningococcal disease? |
|
Anyone can get meningococcal disease, but it is more common in
infants and children. For some adolescents, such as first-year
college students living in dormitories, there is an increased risk
of meningococcal disease. Every year in the United States
approximately 2,500 people are infected and 300 die from the
disease. Other persons at increased risk include household contacts
of a person known to have had this disease, immunocompromised
people, and people traveling to parts of the world where
meningococcal meningitis is prevalent.
|
|
How is
the meningococcus germ spread? |
|
The meningococcus germ is spread by direct close contact with nose
or throat discharges of an infected person.
|
|
High fever, headache, vomiting, stiff neck and a rash are symptoms
of meningococcal disease. The symptoms may appear two to 10 days
after exposure, but usually within five days. Among people who
develop meningococcal disease, 10 to 15 percent die, in spite of
treatment with antibiotics. Of those who live, permanent brain
damage, hearing loss, kidney failure, loss of arms or legs, or
chronic nervous system problems can occur.
|
|
What is
the treatment for meningococcal disease? |
|
Antibiotics, such as penicillin G or ceftriaxone, can be used to
treat people with meningococcal disease.
|
|
Should people who have
been in contact with a diagnosed case of meningococcal meningitis be
treated? |
|
Only people who have been in close contact (household members,
intimate contacts, health care personnel performing mouth-to-mouth
resuscitation, daycare center playmates, etc.) need to be considered
for preventive treatment. Such people are usually advised to obtain
a prescription for a special antibiotic (either rifampin,
ciprofloxacin or ceftriaxone) from their physician. Casual contact,
as might occur in a regular classroom, office or factory setting, is
not usually significant enough to cause concern.
|
|
Is there a vaccine to
prevent meningococcal meningitis? |
|
In February
2005 the CDC recommended a new vaccine, known as Menactra™, for use
to prevent meningococcal disease in people 11 to 55 years of age.
The previously licensed version of this vaccine, Menomune™, is
available for children two to 10 years old and adults older than 55
years. Both vaccines are 85 |
|
to 100 percent
effective in preventing the four kinds of the meningococcus germ
(types A, C, Y, W-135). These four types cause about 70 percent of
the disease in the United States. Because the vaccines do not
include type B, which accounts for about one-third of cases in
adolescents, they do not prevent all cases of meningococcal disease.
|
|
Is the
vaccine safe? Are there adverse side effects to the vaccine?
|
|
Both vaccines are currently available and both are safe and
effective vaccines. However, both vaccines may cause mild and
infrequent side effects, such as redness and pain at the injection
site lasting up to two days.
|
|
Who
should get the meningococcal vaccine? |
|
The vaccine is recommended for all adolescents entering middle
school (11 to 12 years old) and high school (15 years old), and all
first-year college students living in dormitories. However, the
vaccine will benefit all teenagers and young adults in the United
States. Also at increased risk are people with terminal complement
deficiencies or asplenia, some laboratory workers and travelers to
endemic areas of the world.
|
|
What is
the duration of protection from the vaccine? |
|
Menomune™, the older vaccine, requires booster doses every three to
five years. Although research is still pending, the new vaccine,
Menactra™, will probably not require booster doses.
|
|
How do I
get more information about meningococcal disease and vaccination?
|
|
Contact your physician or your student health service. Additional
information is also available on the Web sites of the New York State
Department of Health,
www.nyhealth.gov;
the Centers for Disease Control and Prevention
www.cdc.gov/ncidod/diseases/index.htm;
and the American College Health Association,
www.acha.org.
|
|